Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting

Core Insights - Leap Therapeutics, Inc. announced preclinical data for FL-501, a monoclonal antibody targeting GDF-15, at the AACR Annual Meeting, highlighting its potential in treating cancer cachexia [1][2][3] Group 1: Product Development - FL-501 is engineered for higher affinity to GDF-15 and has a longer plasma half-life compared to competing therapies [5][7] - In preclinical models, FL-501 fully restored body composition, showing effectiveness comparable or superior to clinical-stage antibodies like visugromab and ponsegromab [7] - The company plans to advance FL-501 into clinical trials in 2026 [3] Group 2: Disease Context - Cancer cachexia is a severe condition leading to significant weight loss and reduced quality of life, contributing to cancer-related mortality [3] - High levels of GDF-15 are associated with cancer cachexia symptoms such as loss of appetite and weight loss [5] Group 3: Presentation Details - The poster presentation for FL-501 will take place on April 29, 2025, at the AACR Annual Meeting, under the session category of Experimental and Molecular Therapeutics [5]